1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nova Eye Medical Limited

Nova Eye Medical Limited

EYE.AX
Nova Eye Medical LimitedAU flagAustralian Securities Exchange
0.11
AUD
- -
- -
29.91MMarket Cap
Nova Eye Medical Limited
EYE.AX
(Australian Securities Exchange)

Recent

price

0.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.56
0.5
0.54
0.49
0.49
0.57
0.65
0.59
0.57
0.55
0.09
0.09
0.09
0.11
0.11
0.12
Revenue per Share
0.04
-0.01
0.01
-0.01
0.01
0.02
0.03
-0.01
-0.04
-0.04
0.24
-0.03
-0.05
-0.1
-0.04
-0.04
Basic EPS, GAAP
0.05
- -
0.02
0.01
0.01
0.04
- -
-0.09
-0.02
-0.01
-0.01
-0.01
-0.03
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.13
- -
- -
- -
- -
Dividend per Share
0.38
0.37
0.38
0.37
0.35
0.37
0.43
0.48
0.54
0.46
0.7
0.25
0.21
0.15
0.11
0.08
Book Value per Share
0.37
0.34
0.36
0.34
0.3
0.32
0.39
0.44
0.52
0.44
0.66
0.22
0.16
0.09
0.07
0.05
Tangible Book Value per Share
87
87
87
87
111
111
112
121
138
147
147
148
149
160
204
247
Basic Weighted Avg Shares
49
43
48
43
54
63
73
72
79
82
13
13
14
17
23
29
Sales/Revenue/Turnover
7.95
-0.92
2.05
-0.61
3.54
3.46
8.68
0.25
-7.07
-7.79
-56.19
-38.58
-71.15
-70.45
-38.45
-38.43
Operating Margin (%)
2
2
2
1
1
3
3
3
2
2
1
2
2
2
3
2
Depreciation Expense
4
-1
1
-1
1
2
3
-1
-5
-6
36
-4
-7
-15
-9
-9
Net Income, GAAP
- -
- -
1.59
682.86
39.89
36.15
27.76
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
7.87
-1.64
1.94
-1.91
1.45
2.68
4.15
-1.25
-6.37
-7.07
279.22
-32.52
-54.99
-89.83
-37.68
-30.95
Profit Margin (%)
17
27
16
11
15
18
24
20
41
28
89
22
12
8
9
7
Working Capital
2
1
4
1
1
1
2
- -
6
- -
1
2
1
1
3
2
LT Debt
33
31
32
31
37
40
48
57
75
69
101
35
30
23
21
19
Total Equity
- -
- -
2.42
3.87
2.86
3.1
8.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
2.89
-5.97
2.22
3.9
6.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
12.37
-2.19
2.82
-2.5
2.21
4.21
6.77
-1.68
-7.6
-8.13
41.92
-6.2
-21.92
-56.52
-38.81
-43.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.26%
-24.33%
-11.08%
Free Cash Flow
1,272.03%
47.03%
-5.12%
Net Income, GAAP
-26.45%
4.88%
3.06%
Sales/Revenue/Turnover
3.79%
18.81%
25.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
17
2024
- -
- -
- -
- -
23
2025
- -
- -
- -
- -
29

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.1
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Pulsenmore Ltd. (PULS.TA)
Vicarious Surgical Inc. WT (RBOT-WT)
Cerus Corporation (CERS)
MicroPort NeuroTech Limited (2172.HK)
Xvivo Perfusion AB (publ) (XVIVO.ST)
BioSig Technologies, Inc. (BSGM)
Business
Nova Eye Medical Limited Nova Eye Medical Limited (ASX:EYE) designs, develops, manufactures, markets and sells proprietary surgical devices and technologies primarily for glaucoma treatment, including the iTrack family of minimally invasive glaucoma surgery (MIGS) devices such as iTrack Advance for canaloplasty, catheterization, viscodilation of Schlemm’s canal, fluid infusion or aspiration and trabecular meshwork disruption during goniotomy procedures to restore the eye’s natural outflow pathway and reduce intraocular pressure in open-angle glaucoma patients; the Molteno3 glaucoma drainage device platform for severe and complex glaucoma cases offering enhanced surgical utility, long-term intraocular pressure control and simplified procedures; and the AlphaRET laser technology segment targeting age-related macular degeneration, diabetic retinopathy and retina diseases. The company operates through Glaucoma Surgical Devices and AlphaRET segments, generating majority revenue from Glaucoma Surgical Devices in direct markets led by the United States and Germany, with additional sales via a global network of over 50 distribution partners in Europe, Asia-Pacific including China, Australia and the Americas; it serves eye surgeons treating mild-to-moderate and advanced glaucoma patients seeking alternatives to medications or invasive surgeries like trabeculectomy. Founded in 2020 and headquartered at 107 Rundle Street, Kent Town, South Australia, the company maintains sales headquarters in Fremont, California; manufacturing in Fremont and Dunedin, New Zealand; and subsidiaries including Nova Eye, Inc. in the US, Molteno Ophthalmic Limited in New Zealand and Nova Eye Medical GmbH in Germany following its 2020 acquisition of Molteno Ophthalmology assets. Recent developments include National Medical Products Administration (NMPA) approval for iTrack Advance in China in September 2025 enabling pre-launch activities with an exclusive partner and projected sales growth from late FY26 amid US-China trade monitoring; 32% quarter-on-quarter global sales growth excluding China to US$4.9 million in Q1 FY26 with last-12-months revenue exceeding A$30 million; reaffirmed FY26 sales guidance excluding China of US$21-24 million and EBITDA breakeven targeted in H2 FY26; a A$488,000 Australian government grant in July 2025 with Adelaide University for quantum technology in early eye disease detection; publication of a peer-reviewed study in July-September 2025 affirming iTrack Advance's 24-month safety and efficacy in reducing medication dependence; prominent features at the 43rd European Society of Cataract and Refractive Surgeons Congress and German Society of Ophthalmology Congress in September 2025; and ongoing evaluation of iTrack for targeted ocular drug delivery with pharmaceutical partners.